+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Blood and Bone Marrow Cancer Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2019-2027

  • ID: 4832932
  • Report
  • August 2019
  • Region: Global
  • Acute Market Reports

FEATURED COMPANIES

  • AstraZeneca, Plc.
  • Celgene, Inc.
  • Eli Lilly & Company
  • F.Hoffman La-Roche Ltd.
  • Johnson & Johnson Company
  • Merck & Co., Inc.
The global blood and bone marrow cancer treatment market was valued at US$ 38.8 Bn in 2018 and is expected to reach US$ 74.9 Bn by 2027, expanding at a CAGR of 7.7% from 2019 to 2027.

Market Insights
Blood cancer begins in the bone marrow which is the integral source of stem cells which later are differentiated in different types of blood cells in the human body. Researchers at Bristol Myers Squibb Company have stated that approximately 1.85 million new cases of blood cancer will be diagnosed by 2040 throughout the globe.

Lymphoma is the largest indication segment for blood and bone marrow cancer treatment market. It is prevalent in 2 types Hodgkin lymphoma and Non-Hodgkin lymphoma throughout the globe. The chief variables responsible for its rising prevalence worldwide are increasing prescription of immunosuppressant drugs for treating chronic infections and genetic mutations. Leukemia occurs when the DNA of immature white blood cells gets damaged due to exposure to ionizing radiation, hazardous chemicals, smoking, etc. The prevalence rate of leukemia is highly variable across different ethnic groups with men to women ratio of 1.4.

Chemotherapy is reigning the therapy segment for blood and bone marrow cancer treatment market. The key parameter hold responsible for its increasing demand is the availability of its generic version at affordable cost, drastically reducing the healthcare burden on ailing patients. Oncologists prefer to use them in combination therapy either with radiotherapy or immunotherapy to treat patients showing resistance to first-line drug therapy. Immunotherapy will be the fastest-growing segment during the forecast period owing to its promising drug pipeline for the treatment of blood cancer.

North America representing a market share of 34.6% is dominating the regional segment for blood and bone marrow cancer treatment market. The chief contributing factor for its market supremacy is a growing incidence of blood cancer. As per the research citings of the Leukemia and Lymphoma Society (CDC) figures after every 3 minutes, 1 person in the U.S. is diagnosed with blood cancer. In 2019, approximately 176,200 people in the U.S. are diagnosed with blood cancer in the United States. Existence of key players such as F.Hoffman La-Roche Ltd., Pfizer, Inc., Novartis AG, Merck & Co., Inc., etc further strengthens the market growth. Europe holds a market share of 30.8% owing to the supportive regulatory framework provided by the European Medical Agency for the development and sale of medication for the treatment of blood cancer. The Asia Pacific accounts for 18.4% market share on account of rising public health awareness related to blood cancer & its treatment and developing healthcare infrastructure.
Pharmaceutical companies spearheading the blood and bone marrow cancer treatment market are Bristol Myers Squibb & Company, AstraZeneca, Plc., Eli Lilly & Company, Johnson and Johnson Company, F.Hoffman La-Roche Ltd., Celgene, Inc., Merck & Co., Inc., Novartis AG, Varian Medical Systems, Inc. and Pfizer, Inc.

Key Market Movements
  • Growing incidence of blood cancer worldwide
  • Affordable reimbursement scenario for the medicines employed n the treatment of blood cancer
  • Rising public health awareness and promising drug pipeline to propel the market growth in the near future
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • AstraZeneca, Plc.
  • Celgene, Inc.
  • Eli Lilly & Company
  • F.Hoffman La-Roche Ltd.
  • Johnson & Johnson Company
  • Merck & Co., Inc.
Chapter 1. Preface
1.1. Report Scope and Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. USP and Key Offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Phase I-Secondary Research
1.3.2. Phase II-Primary Research
1.3.3. Approach Adopted
1.3.4. Top-down Approach
1.3.5. Bottom-up Approach
1.3.6. Phase III-Expert Panel Review
1.3.7. Assumptions
1.4. Market Segmentation

Chapter 2. Executive Summary
2.1. Global Blood and Bone Marrow Cancer Treatment Market Portraiture
2.2. Global Blood and Bone Marrow Cancer Treatment Market, by Indication, 2018 (US$ Bn)
2.3. Global Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2018 (US$ Bn)
2.4. Global Blood and Bone Marrow Cancer Treatment Market, by Geography, 2018 (US$ Bn)

Chapter 3. Blood and Bone Marrow Cancer Treatment Market: Dynamics and Future Outlook
3.1. Market Overview
3.2. Drivers
3.3. Challenges
3.4. Opportunities
3.5. Attractive Investment Proposition, by Geography, 2018
3.6. Competitive Analysis: Global Blood and Bone Marrow Cancer Treatment Market, by Key Players, 2018

Chapter 4. Global Blood and Bone Marrow Cancer Treatment Market, by Indication
4.1. Overview
4.2. Multiple Myeloma
4.3. Leukemia
4.4. Lymphoma
4.5. Others

Chapter 5. Global Blood and Bone Marrow Cancer Treatment Market, by Therapy
5.1. Chemotherapy
5.2. Immunotherapy
5.3. Stem Cell Transplant
5.4. Radiotherapy
5.5. Pipeline Analysis
5.5.1. Phase III Drug
5.5.1.1. Eltrombopag
5.5.1.2. Avatrombopag
5.5.1.3. Hetrombopag
5.5.1.4. Omidubicel
5.5.1.5. Fedratinib
5.5.1.6. ATIR101
5.5.1.7. Pegylated Proline Interferon Alpha-2b
5.5.2. Tabular Representation of Phase II and I Pipeline Drugs

Chapter 6. Global Blood and Bone Marrow Cancer Treatment Market, by Geography
6.1. Overview
6.2. North America Blood and Bone Marrow Cancer Treatment Market Analysis, 2017– 2027
6.2.1. North America Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.2.2. North America Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.2.3. North America Blood and Bone Marrow Cancer Treatment Market, by Country, 2017 – 2027 (US$ Bn)
6.2.3.1. U.S.
6.2.3.2. Canada
6.3. Europe Blood and Bone Marrow Cancer Treatment Market Analysis, 2017 – 2027
6.3.1. Europe Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017– 2027 (US$ Bn)
6.3.2. Europe Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.3.3. Europe Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.3.3.1. U.K.
6.3.3.2. Germany
6.3.3.3. Rest of Europe
6.4. Asia Pacific Blood and Bone Marrow Cancer Treatment Market Analysis, 2017 – 2027
6.4.1. Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.4.2. Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017– 2027 (US$ Bn)
6.4.3. Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.4.3.1. China
6.4.3.2. Japan
6.4.3.3. Rest of Asia Pacific
6.5. Latin America Blood and Bone Marrow Cancer Treatment Market Analysis, 2017 – 2027
6.5.1. Latin America Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.5.2. Latin America Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.5.3. Latin America Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.5.3.1. Brazil
6.5.3.2. Mexico
6.5.3.3. Rest of Latin America
6.6. Middle East and Africa Blood and Bone Marrow Cancer Treatment Market Analysis, 2017 – 2027
6.6.1. MEA Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
6.6.2. MEA Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
6.6.3. MEA Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
6.6.3.1. GCC
6.6.3.2. Rest of MEA

Chapter 7. Company Profiles
7.1. AstraZeneca, Plc.
7.1.1. Business Description
7.1.2. Financial Information (Subject to data availability)
7.1.3. Product Portfolio
7.1.4. News Coverage
7.2. Celgene, Inc.
7.3. Bristol Myers Squibb & Company
7.4. Eli Lilly & Company
7.5. Johnson & Johnson Company
7.6. F.Hoffman La-Roche Ltd.
7.7. Merck & Co., Inc.
7.8. Novartis AG
7.9. Pfizer, Inc.
7.10. Varian Medical Systems, Inc.

List of Figures
Figure 1 Blood and Bone Marrow Cancer Treatment Market: Research Methodology
Figure 2 Blood and Bone Marrow Cancer Treatment: Market Segmentation
Figure 3 Global Blood and Bone Marrow Cancer Treatment Market, by Indication, 2018 (US$ Bn)
Figure 4 Global Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2018 (US$ Bn)
Figure 5 Global Blood and Bone Marrow Cancer Treatment Market, by Geography, 2018 (US$ Bn)
Figure 6 Attractive Investment Proposition: by Geography, 2018
Figure 7 Competitive Analysis: Global Blood and Bone Marrow Cancer Treatment Market, by Key Players, 2018
Figure 8 Global Multiple Myeloma Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 9 Global Leukemia Market for Blood and Bone Marrow Cancer Treatment, 2017– 2027 (US$ Bn)
Figure 10 Global Lymphoma Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 11 Global Other Indication Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 12 Global Chemotherapy Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 13 Global Immunotherapy Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 14 Global Stem Cell Transplant Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 15 Global Radiotherapy Market for Blood and Bone Marrow Cancer Treatment, 2017 – 2027 (US$ Bn)
Figure 16 U.S. Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 17 Canada Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 18 U.K. Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 19 Germany Blood and Bone Marrow Cancer Treatment Market, 2017– 2027 (US$ Bn)
Figure 20 Rest of Europe Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 21 China Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 22 Japan Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 23 Rest of Asia Pacific Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 24 Brazil Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 25 Mexico Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 26 Rest of Latin America Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 27 GCC Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)
Figure 28 Rest of MEA Blood and Bone Marrow Cancer Treatment Market, 2017 – 2027 (US$ Bn)

List of Tables
Table 1 Global Blood and Bone Marrow Cancer Treatment Market Portraiture
Table 2 Global Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 3 Global Blood and Bone Marrow Cancer Treatment Market , by Therapy, 2017 – 2027 (US$ Bn)
Table 4 Global Blood and Bone Marrow Cancer Treatment Market, by Geography, 2017 – 2027(US$ Bn)
Table 5 North America Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 6 North America Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 7 North America Blood and Bone Marrow Cancer Treatment Market, by Country, 2017 – 2027 (US$ Bn)
Table 8 Europe Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 9 Europe Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027(US$ Bn)
Table 10 Europe Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 11 Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 12 Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 13 Asia Pacific Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017– 2027 (US$ Bn)
Table 14 Latin America Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 15 Latin America Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 16 Latin America Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 17 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market, by Indication, 2017 – 2027 (US$ Bn)
Table 18 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market, by Therapy, 2017 – 2027 (US$ Bn)
Table 19 Middle East and Africa Blood and Bone Marrow Cancer Treatment Market, by Country/Region, 2017 – 2027 (US$ Bn)
Table 20 AstraZeneca, Plc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 21 Celgene, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 22 Bristol Myers Squibb & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 23 Eli Lilly & Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 24 Johnson and Johnson Company: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 25 F.Hoffman La-Roche Ltd.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 26 Merck & Co., Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 27 Novartis AG: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 28 Pfizer, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Table 29 Varian Medical Systems, Inc.: Company Snapshot (Business Description; Financial Information; Product Portfolio; Key Developments)
Note: Product cover images may vary from those shown
  • AstraZeneca, Plc.
  • Celgene, Inc.
  • Bristol Myers Squibb & Company
  • Eli Lilly & Company
  • Johnson & Johnson Company
  • F.Hoffman La-Roche Ltd.
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Varian Medical Systems, Inc.
Note: Product cover images may vary from those shown
Adroll
adroll